335 related articles for article (PubMed ID: 36073854)
1. Alzheimer's Drug PBT2 Interacts with the Amyloid β 1-42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs.
Summers KL; Roseman G; Schilling KM; Dolgova NV; Pushie MJ; Sokaras D; Kroll T; Harris HH; Millhauser GL; Pickering IJ; George GN
Inorg Chem; 2022 Sep; 61(37):14626-14640. PubMed ID: 36073854
[TBL] [Abstract][Full Text] [Related]
2. Copper(II) Binding to PBT2 Differs from That of Other 8-Hydroxyquinoline Chelators: Implications for the Treatment of Neurodegenerative Protein Misfolding Diseases.
Summers KL; Roseman GP; Sopasis GJ; Millhauser GL; Harris HH; Pickering IJ; George GN
Inorg Chem; 2020 Dec; 59(23):17519-17534. PubMed ID: 33226796
[TBL] [Abstract][Full Text] [Related]
3. PBT2 acts through a different mechanism of action than other 8-hydroxyquinolines: an X-ray fluorescence imaging study.
Summers KL; Dolgova NV; Gagnon KB; Sopasis GJ; James AK; Lai B; Sylvain NJ; Harris HH; Nichol HK; George GN; Pickering IJ
Metallomics; 2020 Dec; 12(12):1979-1994. PubMed ID: 33169753
[TBL] [Abstract][Full Text] [Related]
4. Chelator PBT2 Forms a Ternary Cu
Drew SC
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298218
[TBL] [Abstract][Full Text] [Related]
5. Effect of metal chelators on the aggregation of beta-amyloid peptides in the presence of copper and iron.
Tahmasebinia F; Emadi S
Biometals; 2017 Apr; 30(2):285-293. PubMed ID: 28281098
[TBL] [Abstract][Full Text] [Related]
6. Solution Chemistry of Copper(II) Binding to Substituted 8-Hydroxyquinolines.
Summers KL; Pushie MJ; Sopasis GJ; James AK; Dolgova NV; Sokaras D; Kroll T; Harris HH; Pickering IJ; George GN
Inorg Chem; 2020 Oct; 59(19):13858-13874. PubMed ID: 32936627
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic redistribution of metal ions to treat Alzheimer's disease.
Crouch PJ; Barnham KJ
Acc Chem Res; 2012 Sep; 45(9):1604-11. PubMed ID: 22747493
[TBL] [Abstract][Full Text] [Related]
8. 8-Hydroxyquinoline Schiff-base compounds as antioxidants and modulators of copper-mediated Aβ peptide aggregation.
Gomes LM; Vieira RP; Jones MR; Wang MC; Dyrager C; Souza-Fagundes EM; Da Silva JG; Storr T; Beraldo H
J Inorg Biochem; 2014 Oct; 139():106-16. PubMed ID: 25019963
[TBL] [Abstract][Full Text] [Related]
9. Simple and mixed complexes of copper(II) with 8-hydroxyquinoline derivatives and amino acids: Characterization in solution and potential biological implications.
Sgarlata C; Arena G; Bonomo RP; Giuffrida A; Tabbì G
J Inorg Biochem; 2018 Mar; 180():89-100. PubMed ID: 29247871
[TBL] [Abstract][Full Text] [Related]
10. X-ray Absorption Spectroscopy Investigations of Copper(II) Coordination in the Human Amyloid β Peptide.
Summers KL; Schilling KM; Roseman G; Markham KA; Dolgova NV; Kroll T; Sokaras D; Millhauser GL; Pickering IJ; George GN
Inorg Chem; 2019 May; 58(9):6294-6311. PubMed ID: 31013069
[TBL] [Abstract][Full Text] [Related]
11. New Hydroxyquinoline-Based Derivatives as Potent Modulators of Amyloid-β Aggregations.
Fu CL; Hsu LS; Liao YF; Hu MK
Arch Pharm (Weinheim); 2016 May; 349(5):327-41. PubMed ID: 27027880
[TBL] [Abstract][Full Text] [Related]
12. The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity.
Crouch PJ; Savva MS; Hung LW; Donnelly PS; Mot AI; Parker SJ; Greenough MA; Volitakis I; Adlard PA; Cherny RA; Masters CL; Bush AI; Barnham KJ; White AR
J Neurochem; 2011 Oct; 119(1):220-30. PubMed ID: 21797865
[TBL] [Abstract][Full Text] [Related]
13. Stabilization of nontoxic Aβ-oligomers: insights into the mechanism of action of hydroxyquinolines in Alzheimer's disease.
Ryan TM; Roberts BR; McColl G; Hare DJ; Doble PA; Li QX; Lind M; Roberts AM; Mertens HD; Kirby N; Pham CL; Hinds MG; Adlard PA; Barnham KJ; Curtain CC; Masters CL
J Neurosci; 2015 Feb; 35(7):2871-84. PubMed ID: 25698727
[TBL] [Abstract][Full Text] [Related]
14. Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy.
Ferrada E; Arancibia V; Loeb B; Norambuena E; Olea-Azar C; Huidobro-Toro JP
Neurotoxicology; 2007 May; 28(3):445-9. PubMed ID: 17382398
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
16. Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited.
Mancino AM; Hindo SS; Kochi A; Lim MH
Inorg Chem; 2009 Oct; 48(20):9596-8. PubMed ID: 19817493
[TBL] [Abstract][Full Text] [Related]
17. Preparation and study of new poly-8-hydroxyquinoline chelators for an anti-Alzheimer strategy.
Deraeve C; Boldron C; Maraval A; Mazarguil H; Gornitzka H; Vendier L; Pitié M; Meunier B
Chemistry; 2008; 14(2):682-96. PubMed ID: 17969218
[TBL] [Abstract][Full Text] [Related]
18. Mixed ligand Cu2+ complexes of a model therapeutic with Alzheimer's amyloid-β peptide and monoamine neurotransmitters.
Kenche VB; Zawisza I; Masters CL; Bal W; Barnham KJ; Drew SC
Inorg Chem; 2013 Apr; 52(8):4303-18. PubMed ID: 23537393
[TBL] [Abstract][Full Text] [Related]
19. Disaggregation ability of different chelating molecules on copper ion-triggered amyloid fibers.
Zhu L; Han Y; He C; Huang X; Wang Y
J Phys Chem B; 2014 Aug; 118(31):9298-305. PubMed ID: 25051063
[TBL] [Abstract][Full Text] [Related]
20. The redox chemistry of the Alzheimer's disease amyloid beta peptide.
Smith DG; Cappai R; Barnham KJ
Biochim Biophys Acta; 2007 Aug; 1768(8):1976-90. PubMed ID: 17433250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
